VitalHub Announces Q4 2024 Conference Call Date
TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to...
Day: March 17, 2025
Bon Natural Life Limited Announces Pricing of $12 Million Best Efforts Offering
XI’AN, China, March 17, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), one of...
New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution
Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, favorable...
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an...
Myhal Family Foundation Makes Transformative Gift to the Future of St. Joe’s
Prominent Philanthropic Family inspires community to give back generouslyTORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- St. Joseph’s Health Centre Foundation...
Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader
CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (XRAY) today announced that...
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected...
Lirum Therapeutics Announces Debut of LX-101 Results in Thyroid Eye Disease, Selected for Presentation at the 2025 NANOS Annual Meeting
New York, NY, March 17, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on...
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency
TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the “Company”), a specialty pharmaceutical company...
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively Cash...
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX),...
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Bitterroot Bio to Present Detailed Results from Phase 1 Study of BRB-002 at American College of Cardiology Annual Scientific Session 2025
PALO ALTO, Calif. and NEEDHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in...
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX 1416...
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new...
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing...
Extendicare Announces March 2025 Dividend of C$0.042 per Share
MARKHAM, Ontario, March 17, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has...
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy...
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX),...
